Following positive early data from an ongoing clinical trial, Tempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental therapy for myeloma that is being developed by Hebei Senlang Biotechnology. The newly executed option gives Tempest rights to the therapy, which the company is renaming TPST-4903, in all countries outside […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.